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Human Papillomavirus (HPV) infection plays a crucial role in the development of cervical lesions and
tumors, however most lesions containing high-risk HPVs do not progress to cervical tumors. Some studies
suggest that the use of oral contraceptives may increase the risk of cervical carcinogenesis, but this has
not been conﬁrmed by all the studies. Cytokines are important molecules that act in the defense of an
organism against viral infections. Several genetic studies have attempted to correlate cytokine polymor-
phisms with human diseases, including cancer. The signiﬁcance of IL10 polymorphisms for cancer is that
they have both immunosuppressive and antiangiogenic properties. We aimed to investigate the role of
promoter polymorphisms in the IL10 gene in women with cervical lesions associated with HPV infection,
in the presence of the use of oral contraceptives. Using High Resolution Melt analysis (HRM), we analyzed
an SNP -1082A/G and -819C/T in interleukin-10 promoter region in 364 Brazilian women: 171 with cervical
lesions and HPV infection, and 193 with normal cytological results and HPV-negative. We observed no
signiﬁcant differences in genotype and allele frequencies in the two loci between patients and healthy
controls. Furthermore, in the haplotype analysis of IL10, we found that CA haplotype was signiﬁcantly
more frequent in patients infected with HPV than in the control group (p = 0.0188). We did not ﬁnd
any genotype and allelic association of the IL10 gene polymorphisms between cases and controls. How-
ever, in this study, when the HPV-positive patients were stratiﬁed according to their use of contracep-
tives, we found a signiﬁcant association between the -1082G allele (p = 0.0162) and -1082GG genotype
(p = 0.0332) among HPV-infected patients who used oral contraceptives. Our ﬁndings suggest
that -1082A/G gene polymorphism represents a greater susceptibility to progressive cervical lesions in
HPV- infected women who use oral contraceptives.
 2013 Elsevier B.V. All rights reserved.1. Introduction
At present, cervical cancer represents 9% of cases of female can-
cer and is the third leading cause of cancer death in women world-wide, with more than 529.800 new cases and 275.100 deaths per
year (Jemal et al., 2011; Freitas et al., 2012).
It is generally accepted that Human Papillomavirus (HPV) infec-
tion plays a crucial role in the development of cervical lesions, and
it is estimated that about 98% of cervical tumors are associated
with HPV (zur Hausen, 1996; Baseman and Koutsky, 2005). The
contribution of HPV infection in cervical disease depends on the
HPV type and period of viral replication in the epithelial cells of
the cervical transformation zone (Harmsel et al., 1999; Hopman
et al., 2000). However, most lesions containing high-risk HPVs do
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cofactors may also be involved in predisposition to disease (Freitas
et al., 2012). Some studies suggest that the use of oral contracep-
tives may increase the risk of cervical carcinogenesis (Ylitalo
et al., 1999), but this has not been conﬁrmed in all the studies
(Thomas et al., 2001).
The host immune response is also important for the control of
neoplastic growth and viral infection. The prevalence of HPV infec-
tion and progression of cervical lesions is more frequent in immu-
nodeﬁcient women than immunocompetent women (Parkin et al.,
2002).
Cytokines are molecules that are important in the defense of
organisms against viral infections. They are produced by macro-
phages, monocytes, and lymphocytes, and act in an indirect way
by determining a pattern of immune response or directly by inhib-
iting viral replication (de Waal Malefyt et al., 1991; Fernandes
et al., 2005). IL-10 is of particular interest with regard to cancer be-
cause it has both immunosuppressive (potentially cancer-promot-
ing) and antiangiogenic (potentially cancer-inhibiting) properties
(Howell and Rose-Zerilli, 2007).
The IL10 gene is located on human chromosome 1, between
1q31 and 1q32 (Eskdale et al., 1997). Many single nucleotide poly-
morphisms (SNPs) have been detected within the cytokine gene
sequence, especially within the promoter regions, including
IL10 -1082A/G (rs1800870), -819C/T (rs1800871) and -592A/C
(rs1800872). These polymorphisms may be associated with differ-
ential levels of gene transcription, since some alleles can produce
low, medium and high amounts of IL-10 (Eskdale et al., 1998).
The ability to secrete different cytokines seems to be important
in the immune response (Hutchinson et al., 1999). Genetic studies
have been conducted in an attempt to correlate these cytokine
polymorphisms with some types of cancer, although with mixed
results (Stanczuk et al., 2001; Roh et al., 2002; Szoke et al., 2004;
Matsumoto et al., 2010).
Thus, in this work, a case-control study was carried out to
investigate the role of IL10 gene promoter polymorphisms
(-1082A/G and -819C/T) in women with cervical lesions associated
with HPV infection in the presence of environmental cofactors.2. Materials and methods
2.1. Study group
The samples evaluated in this study were obtained by cervical
scraping from a total of 364 voluntary patients who underwent
cervical cancer screening at the Gynecological Clinic at the ‘‘Oswal-
do Cruz University Hospital (HUOC)’’ in Pernambuco State, North-
eastern Brazil. 171 women (median age 34.7 ± 10.8) with cervical
abnormalities (low-grade squamous intraepithelial lesions and
high-grade squamous intraepithelial lesions) and HPV infection
were classiﬁed as cases. In addition, 193 women (median age
34.7 ± 11.2) with normal cytological results and HPV-negative,
were classiﬁed as controls. All the patients and control subjects
were from the same geographical area (Northeastern, Brazil), and
belonged to the same ethnic group; they were HIV-negative and
not being treated with immunosuppressive medication.
A short questionnaire about social and demographic features
such as age, sexual behavior and the use of oral contraceptives
was carried out to investigate the increased risk of cervical neopla-
sia. Approval of the Ethical Committee (HUOC/PROCAPE 64/2010)
and informed consent from all women in the study were obtained.
The cervical cells collected with cytobrush were placed in phos-
phate-buffered saline (PBS) pH 7.4 and stored at 80 C prior to
DNA extraction.2.2. DNA isolation
Genomic DNA was extracted from cervical cells using the
DNeasy Blood and Tissue Kit (Qiagen), in accordance with the fol-
lowing stages: resuspension of the cell pellet in PBS (pH 7.4), cell
lysis, puriﬁcation, and washing and drying the material to obtain
the DNA elution.
2.3. HPV analysis
Human Papillomavirus DNA was detected by employing the
PCR method based on the ampliﬁcation of the viral L1 gene frag-
ment using degenerate primers MY09 (50-CGTCCMARRGGAWACT-
GATC-30) and MY11 (50-GCMCAGGGWCATAAYAATGG-30) (Manos
et al., 1989; Karlsen et al., 1996).
The MY09/11 PCR that was tested positive was puriﬁed with the
Invisorb Fragment Cleanup (Invitek) kit and sequenced by using
ABI PRISM BigDyeTM Terminator Cycle Sequencing v3.1 Ready
reaction (Applied Biosystems). The HPV genotype was identiﬁed
by comparing the sequence with that reported in GenBank using
Basic Local Alignment Search Tool (BLAST), available at <http://
www.ncbi.nlm.nih.gov/blast>.
2.4. Genotyping of IL10 -1082A/G and -819C/T polymorphisms
The genotyping of polymorphisms in the promoter of IL10 gene,
-1082A/G (rs1800896) and -819C/T (rs1800871), was performed by
means of the Rotor-Gene 6000 apparatus (Rotor-Gene, Uni-
science-Cobert Research). This apparatus used High Resolution
Melt analysis (HRM), a ﬂuorescence-based method for rapid muta-
tion screening after standard PCR ampliﬁcation in the presence of
dsDNA intercalating EvaGreen ﬂuorescent dye.
HRM was carried out for the detection of DNA sequence vari-
ants and was ﬁrst applied for genotyping (Wittwer et al., 2003).
This simple approach allowed us to discriminate between the three
possible IL10 promoter alleles immediately. For each allele, a spe-
ciﬁc melting curve is created at the end of the precise warming
of the amplicon. The decreasing ﬂuorescence signal is converted
to a graphic representation and each genotype gives a melt curve
that is slightly different from the others. With this simple assay
it is possible to distinguish between all three alleles (Vossen
et al., 2009).
The PCR ampliﬁcation reactions were performed in a ﬁnal vol-
ume of 25 ll, using HRM PCR Master Mix 2X (Qiagen), 10 lM of
each primer (Supplementary Table S1) and roughly 50 ng of geno-
mic DNA as a template. After ampliﬁcation, all the samples were
analyzed by heating to 95 C for 1 min, cooling to 40 C for 1 min
and then melting at 0.1 C/s with continuous acquisition of ﬂuores-
cence from 78 to 88 C for -819C/T and 75 to 85 C for -1082A/G.
Some homozygous and heterozygous samples were analyzed by
direct sequencing to validate the data obtained by the HRM meth-
od. The same results were observed in both techniques.
2.5. Statistical analysis
A chi-square test was used to verify the Hardy–Weinberg equi-
librium using the Genotype Transposer program (Version 1.0) and
Fisher’s exact test was used for pair-wise comparison of alleles and
genotypes using contingency tables as appropriate, through the
open-source R package (available at the <http://www.r-pro-
ject.orgsite>). The genetic frequency testing and association analy-
sis between the comparison groups and risk factors were
performed with UNPHASED v.3.121 (Dudbridge, 2008). This soft-
ware carries out a retrospective likelihood test (the probability of
observing genotypes for given phenotypes) using a multinomial lo-
gistic regression model. HAPLOVIEW v.4.2 was used to evaluate the
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and haplotype associations (Barrett et al., 2005). All the tests were
two-tailed and the level of signiﬁcance for all the statistical results
was set at p < 0.05.
3. Results
3.1. Characteristics of study populations
The features of the cases and controls employed in this study
are summarized in Supplementary Table S2. The ages of the pa-
tients with HPV-positive cervical abnormality ranged from 18 to
63 (average 34.7 ± 10.8), and the age of the controls ranged from
18 to 65 years (average 34.7 ± 11.2). Signiﬁcant differences were
observed between the cases and controls with regard to the use
of contraceptives (p = 0.04) and the number of sexual partners
(p < 0.001). The age variable was also taken into account to deter-
mine its association with the development of cervical lesions and
presence of HPV, but no signiﬁcant association was found
(p = 0.13).
3.2. HPV analysis
A total of 364 DNA cervical cell samples were examined for the
presence of HPV, using L1 consensus primers (MY09/MY11): 171
(47%) were positive for HPV and 193 (52%) were HPV-negative.
The most common high-risk HPV type, HPV-16, was found in 49
(28.6%) of the HPV-positive patients. The other HPV types which
showed a notable prevalence were Types 31 (19.9%), 58 (5.8%)
and 33 (4.7%). Nineteen patients had co-infections. Details of spe-
ciﬁc HPV type frequencies are shown in Supplementary Table S3.
3.3. Genotyping of IL10 -819C/T and -1082A/G polymorphisms
The results of the experiment with IL10 -819C/T and -1082A/G
polymorphisms are displayed in Table 1. All the polymorphisms
(in both cases and controls groups) were in conformed to Hardy–
Weinberg equilibrium.
With regard to the IL10 -819C/T polymorphism for the case group,
the frequencies of the alleles C and T were 0.59 and 0.41, respec-Table 1
IL10 -819C/T and -1082A/G polymorphisms in patients with HPV and cervical lesions of low
Cases Healthy Contro
Polymorphisms
Total (n = 171) HPV/LSILa (n = 89) HPV/HSILb (n = 82) (n = 193)
IL10 -819C/T
Alelles
C 202 (0.59) 105 (0.59) 97 (0.59) 239 (0.62)
T 140 (0.41) 73 (0.41) 67 (0.41) 147 (0.38)
Genotypes
CC 56 (0.33) 29 (0.33) 27 (0.33) 76 (0.39)
CT 90 (0.53) 47 (0.53) 43 (0.52) 87 (0.45)
TT 25 (0.14) 13 (0.19) 12 (0.15) 30 (0.16)
IL10 -1082A/G
Alelles
A 190 (0.56) 102 (0.57) 88 (0.54) 229 (0.59)
G 152 (0.44) 76 (0.43) 76 (0.46) 157 (0.41)
Genotypes
AA 56 (0.33) 30 (0.34) 26 (0.32) 69 (0.36)
AG 78 (0.46) 42 (0.47) 36 (0.44) 91 (0.47)
GG 37 (0.21) 17 (0.19) 20 (0.24) 33 (0.17)
p < 0.05 – Statistically signiﬁcant.
HC: Healthy Control.
a HPV/LSIL: HPV + low-grade squamous intraepithelial lesions.
b HPV/HSIL: HPV + high-grade squamous intraepithelial lesions.tively. For the control group, the C and T frequencies were 0.63
and 0.37, respectively. The observed genotype frequency in the case
groupwas 33% (CC), 52% (CT) and 15% (TT). In the control group, the
genotype frequency was 41% (CC), 44% (CT) and 15% (TT). Thus, CC
was the genotype used as a reference-point, and the relative disease
association of CT and TT genotypes was expressed by calculating
the odds ratios (OR) and their 95% CI (Table 1).
With regard to the allele frequencies, there was no statistically
signiﬁcant differences between patients with HPV/cervical lesion
and the healthy controls (C vs. T allele: OR = 1.15, 95% CI: 0.84–
1.57 and p = 0.36). In the case of the genotypic frequencies, as sta-
ted earlier, no differences were identiﬁed between the control and
case groups (CC vs. CT genotype: OR = 1.48, CI: 0.92–2.39 and
p = 0.11; CC vs. TT genotype: OR = 1.15, CI: 0.58–2.27 and
p = 0.75 (Table 1).
A multivariate logistic regression analysis based on environ-
mental risk factors, showed that the use of contraceptives and
number of sexual partners did not indicate any signiﬁcant differ-
ences in either genotypic or allelic frequencies of IL10 -819C/T poly-
morphisms (data not shown).
When the IL10 -1082A/G polymorphisms were analyzed for the
case group, the frequencies of the alleles A and G were 0.56 and
0.44, respectively. With respect to the control group, the A and G
frequencies were 0.60 and 0.40, respectively. The genotype fre-
quency in the case group was 33% (AA), 45% (AG) and 22% (GG).
In the control group, the genotype frequency was 36% (AA), 48%
(AG) and 16% (GG). For this reason, AA was regarded as the refer-
ence-point of the genotype, and the relative association of the AG
and GG genotype with disease was expressed by calculating the
odds ratios (OR) and their 95% CI (Table 1).
With regard to the allele frequencies, there were no statistically
signiﬁcant differences between patients with HPV/cervical lesions
and the healthy control groups (A vs. G allele: OR = 1.18, 95% CI:
0.86-1.60 and p = 0.29). As observed earlier, no differences were
identiﬁed for the genotypic frequencies, between the control and
case groups (AA vs. AG genotype: OR = 1.02, CI: 0.62–1.65 and
p = 1; AA vs. GG genotype: OR = 1.44, CI: 0.76–2.73 and p = 0.23
(Table 1).
A multivariate logistic regression analysis using environmental
risk factors showed that the use of contraceptives revealed adegree (LSIL) and high degree (HSIL) and healthy patients.
l p-value; OR [95% C.I.]
Total vs. HC HPV/LSIL vs. HC HPV/HSIL vs. HC
Reference Reference Reference
0.448; 1.13 [0.83–1.53] 0.517; 1.13 [0.77–1.65] 0.567; 1.12 [0.76–1.66]
Reference Reference Reference
0.167; 1.40 [0.87–2.27] 0.263; 1.41[0.78–2.57] 0.314; 1.39 [0.76–2.58]
0.747; 1.13[0.57–2.22] 0.841; 1.13 [0.47–2.62] 0.837; 1.12 [0.46–2.66]
Reference Reference Reference
0.329; 1.17 [0.86–1.58] 0.713; 1.09 [0.74–1.58] 0.222; 1.26 [0.86–1.85]
Reference Reference Reference
0.906; 1.05 [0.65–1.73] 0.886; 1.06 [0.58–1.95] 1.000; 1.05 [0.56–1.99]
0.299; 1.38 [0.74–2.59] 0.710; 1.18 [0.53–2.59] 0.200; 1.60 [0.74–3.48]
Table 2
Interaction analysis between environmental risk factor (contraceptive use), patients
HPV infected (comparison sub-group in patients HPV infected who use and do not use
oral contraceptive) and genotypes/alleles of IL10 -1082A/G.
HPV and no
contraceptive use
HPV and
contraceptive
use
OR (95% CI)
Alelles
A 114 (0.51) 76 (0.64) 1
G 110 (0.49) 42 (0.36) 1.75 (1.10–2.76)
Association v2 = 5.78 / p-value = 0.0162
Genotypes
AA 29 (0.46) 27 (0.46) 1
AG 56 (0.37) 22 (0.37) 1.06 (0.44–2.55)
GG 27 (0.17) 10 (0.17) 2.51 (1.02–6.15)
Association v2 = 6.81 / p-value = 0.0332
p < 0.05 – Statistically signiﬁcant.
v2: Chi-square tests.
Table 3
Haplotype frequencies and association between case and control groups.
Haplotype rs1800871 rs1800896 Case – control
frequencies
Association
1 C A 0.2425–0.3408 v2 = 8.02
2 C G 0.3481–0.2784 df = 3
3 T A 0.3130–0.2557 p-value = 0.0456
4 T G 0.0963– 0.1252
Statistically signiﬁcant value is shown in bold.
v2: Chi-square tests.
df: degree of freedom.
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ble 2) in HPV-infected patients. However, with regard to the num-
ber of sexual partners, there was no signiﬁcant difference in either
genotypic or allelic frequencies for IL10 -1082A/G polymorphisms
(data not shown).3.4. Haplotype analysis of the IL10 gene
Haplotype analyses were conducted and the four possible hap-
lotype frequencies are shown in Table 3. Despite the proximity of
these two polymorphic sites of the IL10 gene, the linkage disequi-
librium coefﬁcient of 0.471 was not high (p < 0.001). Haplotype
analysis suggests that there may be an interaction between the
two sites, with a haplotype distribution between the HPV-infected
patients and control group. Global haplotype association was sig-
niﬁcant with a p-value of 0.0456 (Table 3). Among four possible
haplotypes, only haplotype ‘‘1’’ (CA) was signiﬁcantly more fre-
quent in HPV-infected patients than the control group (v2 = 5.52,
p = 0.0188; OR = 1.91 [1.21–3.04]).4. Discussion
The ability to produce different amounts of cytokines varies
among individuals, and these differences may be genetically deter-
mined. Several studies have evaluated the possible inﬂuence of ge-
netic factors and cytokine production on cervical lesions
(Fernandes et al., 2005, 2008; Sharma et al., 2007).
This study has focused on whether the IL10 promoter polymor-
phisms -1082A/G and -819C/T can inﬂuence the development of cer-
vical cancer associated with HPV infection, in the presence of
environmental cofactors. Our data did not show signiﬁcant differ-
ences in the allele and genotype frequencies between the IL10 pro-
moter polymorphisms -819C/T and -1082A/G or any HPV-related
cervical abnormalities. Roh et al. (2002), corroborated our ﬁndingsthat there was no apparent relationship between the IL10 gene
promoter polymorphisms and the risk of cervical cancer. We also
found that the linkage disequilibrium between position -819 and
-1082 polymorphisms is not high. This may be surprising given
that they are only 263 nucleotides apart and there are no interven-
ing introns. However, this is congruent with other studies indicat-
ing that recombination frequency is not strictly proportional to
chromosomal distance, and it is sensitive to ancestral effects; for
example, Drysdale et al. (2000) found that ‘‘some pairs of close
sites have reduced levels of linkage disequilibrium relative to more
spaced pairs of sites’’. Four possible haplotypes were demonstrated
in the sample population and a signiﬁcant genetic predisposition of
haplotype CA (‘‘1’’) was found for cases, rather than the controls
(OR = 1.91, CI 1.21–3.04, p = 0.0188).
Although we did not ﬁnd genotypic and allelic association of the
IL10 gene polymorphisms between the cases and controls in this
study, when HPV-positive patients were stratiﬁed according to
their use of oral contraceptives, we observed a signiﬁcant associa-
tion between the -1082G allele/-1082GG genotype and HPV infection
in these patients. According to Gravitt et al. (2003), the IL-10 levels
at the uterine cervix are inﬂuenced by cofactors like contracep-
tives. Our data showed that the -1082G allele and -1082GG genotype
were associated with a signiﬁcantly increased risk of cervical can-
cer (OR = 1.71, CI 1.10–2.76, p = 0.0162) and (OR = 2.51, CI 1.02–
6.15, p = 0.0332), respectively. To the best of our knowledge, this
is the ﬁrst study that has investigated this type of association be-
tween the IL10 gene polymorphisms and use of oral contraceptives,
when there are HPV-related cervical abnormalities. There are con-
troversial studies regarding the association of IL10 gene polymor-
phism and cervical cancer (Stanczuk et al., 2001; Roh et al.,
2002; Szoke et al., 2004; Matsumoto et al., 2010), and perhaps
one of the probable reasons for these divergent is the fact external
factors are involved such as the use of oral contraceptives, which
this study found led to an association between the polymorphism
in the -1082 region and the risk of developing cervical cancer in the
presence of viral infection. This means that this cofactor may cause
an increased risk of cervical cancer in HPV-infected patients that
carry the polymorphism -1082A/G, since these steroid hormones
can accelerate the viral oncogene expression that is present in
the HPV cellular genome (Salazar et al., 2005).
In HPV, the transcription of E6 and E7 oncogenes is controlled
by the regulation of the long control region (LCR). Furthermore,
the LCR has been shown to contain response elements for proges-
terone and glucocorticoid (Park et al., 2003). In theory, progester-
one and estrogens stimulate HPV-16 gene expression due to
activation by nuclear receptors, followed by the interaction of
the activated receptors with hormone-responsive elements within
the LCR of HPV-16 (Chen et al., 1996). In addition, studies indicate
that the use of oral contraceptives is a possible risk factor in pro-
gressive cervical cancers (Brinton et al., 1986; Hakama et al.,
1993). Some reports have shown a correlation between the dura-
tion of the use of oral contraceptives and the presence of cervical
intraepithelial neoplasia and HPV-associated cervical cancer (Hil-
desheim et al., 1990; Bosch et al., 1995), and that the risk of cervi-
cal cancer induced by HPV is doubled by prolonged use (Brisson
et al., 1994). In studies conducted by Chen et al. (1996) it was dem-
onstrated that the differential enhancement of HPV-16 gene
expression was induced by some of the progesterones and
estrogens.
With regard to the HPV vaccine Nardelli-Haeﬂiger et al. (2003)
reported that women that used contraceptives and who received
the HPV vaccine, showed a considerable variation of serum and
cervical concentrations of anti-HPV type 16 antibodies after vacci-
nation, compared with those who did not use them. It can be as-
sumed that hormonal modulation of immune cell function may
cause a variation in the immune response to the HPV vaccine
36 B.S. Chagas et al. / Infection, Genetics and Evolution 19 (2013) 32–37which can result in differences in the immunogenicity and efﬁcacy
of the vaccines (Marks et al., 2010).
The ability to secrete different cytokines appears to be impor-
tant in the immune response against HPV infection and the devel-
opment of cervical lesions. However, few studies have evaluated
the cytokine polymorphisms in women who have cervical HPV-re-
lated lesions. Abnormal IL-10 production has already been re-
ported in women with cervical precancerous lesions and invasive
cancer (Giannini et al., 1998). Mota et al. (1999) demonstrated that
the levels of the immunosuppressive cytokine IL-10 increased in
cervical intraepithelial lesions, compared with normal cervices
where the IL10 is rarely detected (El-Sherif et al., 2001).
In evaluating the -1082 polymorphism in the IL10 gene, Stanc-
zuk et al. (2001) demonstrated that women with cervical cancer
that carries the allele G appear to be immunogenetically predis-
posed to produce high levels of IL-10. Increased levels of IL-10 in
HPV-infected women who have cervical lesions, compared with
the women with normal uterine cervices, suggests the occurrence
of local immunosuppression. In contrast, IL-10 inhibits antigen
presentation, the functioning of the cytotoxic T cells, the prolifera-
tion of T cells and secretion of proinﬂammatory cytokines, which
leads to the development of cervical lesions after HPV infection
(Giannini et al., 2002).
In summary, in this case-control study, it was found that the
IL10 polymorphisms -1082A/G and -819C/T had no effect on cervical
carcinogenesis in the studied population. However, we discovered
that IL10 -1082A/G gene polymorphism was signiﬁcantly associated
with HPV-infected patients that use oral contraceptives. In addi-
tion, the CA haplotype was associated with the risk of cervical can-
cer to a signiﬁcant degree. The main ﬁnding of our study suggests
that genetic polymorphism of IL10 -1082A/G represents a risk to the
susceptibility, development and progression of cervical lesions in
HPV-infected women who use oral contraceptives. If the associa-
tion between cytokine gene polymorphisms and the development
of cervical cancer can be fully understood, this can lead to a com-
prehensive view of the immunological control of HPV infection.Funding
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